Phase 3 Start

AGIO: Phase3_Start: A Phase 2/3, Double-blind, Randomized, Placebo-Controlled, Multicenter, Efficacy, Safety, and Pharmacokinetics Study of AG-236 in Subjects With Polycythemia Vera

Name: Phase3_Start: A Phase 2/3, Double-blind, Randomized, Placebo-Controlled, Multicenter, Efficacy, Safety, and Pharmacokinetics Study of AG-236 in Subjects With Polycythemia Vera
Start: 2026-11-01
End: 2026-11-01

November 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: November 1, 2026
Company: AGIOS PHARMACEUTICALS, INC. (AGIO)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: A Phase 2/3, Double-blind, Randomized, Placebo-Controlled, Multicenter, Efficacy, Safety, and Pharmacokinetics Study of AG-236 in Subjects With Polycythemia Vera

November 1, 2026

AGIO overview →

Company: AGIOS PHARMACEUTICALS, INC. (AGIO)